Related references
Note: Only part of the references are listed.The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target
Shuang G. Zhao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Leeat Keren et al.
CELL (2018)
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Evolution of Metastases in Space and Time under Immune Selection
Mihaela Angelova et al.
CELL (2018)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao et al.
NATURE MEDICINE (2017)
Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival
Anna Berthel et al.
ONCOIMMUNOLOGY (2017)
Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Carla Calagua et al.
CLINICAL CANCER RESEARCH (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses
Serena S. Kwek et al.
ONCOIMMUNOLOGY (2016)
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
Debraj GuhaThakurta et al.
CLINICAL CANCER RESEARCH (2015)
Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis
Esther H. J. Hamoen et al.
EUROPEAN UROLOGY (2015)
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
A. M. Martin et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury
Christopher R. Heery et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
Caroline Jochems et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis
Jo A. Tucker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets
Benedetto Farsaci et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Television Viewing and Time Spent Sedentary in Relation to Cancer Risk: A Meta-Analysis
Daniela Schmid et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
Ahmad A. Tarhini et al.
PLOS ONE (2014)
Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
James L. Gulley et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Abstract 5601: The role of UDP-Glucuronosyltransferases in human breast cancers
Athena Starlard-Davenport et al.
CANCER RESEARCH (2012)
The mean apparent diffusion coefficient value (ADCmean) on primary cervical cancer is a predictive marker for disease recurrence
Keiichiro Nakamura et al.
GYNECOLOGIC ONCOLOGY (2012)
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination
Matteo Vergati et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity
Caroline Jochems et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2011)
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L. Gulley et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
Ravi A. Madan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
PA Antony et al.
JOURNAL OF IMMUNOLOGY (2005)
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
EM Janssen et al.
NATURE (2003)
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer
J Gulley et al.
PROSTATE (2002)
Share Paper
